Logo image of ACT.DE

ALZCHEM GROUP AG (ACT.DE) Stock Fundamental Analysis

Europe - Frankfurt Stock Exchange - FRA:ACT - DE000A2YNT30 - Common Stock

162 EUR
+1 (+0.62%)
Last: 1/16/2026, 7:00:00 PM
Fundamental Rating

7

We assign a fundamental rating of 7 out of 10 to ACT. ACT was compared to 69 industry peers in the Chemicals industry. Both the health and profitability get an excellent rating, making ACT a very profitable company, without any liquidiy or solvency issues. ACT has a correct valuation and a medium growth rate. With these ratings, ACT could be worth investigating further for quality investing!.


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

  • ACT had positive earnings in the past year.
  • ACT had a positive operating cash flow in the past year.
  • Each year in the past 5 years ACT has been profitable.
  • ACT had a positive operating cash flow in 4 of the past 5 years.
ACT.DE Yearly Net Income VS EBIT VS OCF VS FCFACT.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M 100M

1.2 Ratios

  • ACT has a Return On Assets of 10.49%. This is amongst the best in the industry. ACT outperforms 95.65% of its industry peers.
  • With an excellent Return On Equity value of 26.47%, ACT belongs to the best of the industry, outperforming 95.65% of the companies in the same industry.
  • The Return On Invested Capital of ACT (13.45%) is better than 92.75% of its industry peers.
  • ACT had an Average Return On Invested Capital over the past 3 years of 12.06%. This is significantly above the industry average of 6.95%.
  • The last Return On Invested Capital (13.45%) for ACT is above the 3 year average (12.06%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 10.49%
ROE 26.47%
ROIC 13.45%
ROA(3y)8.81%
ROA(5y)7.86%
ROE(3y)22.87%
ROE(5y)25.91%
ROIC(3y)12.06%
ROIC(5y)10.63%
ACT.DE Yearly ROA, ROE, ROICACT.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

  • ACT has a better Profit Margin (10.97%) than 84.06% of its industry peers.
  • In the last couple of years the Profit Margin of ACT has grown nicely.
  • Looking at the Operating Margin, with a value of 15.93%, ACT belongs to the top of the industry, outperforming 85.51% of the companies in the same industry.
  • ACT's Operating Margin has improved in the last couple of years.
  • ACT has a Gross Margin of 66.55%. This is amongst the best in the industry. ACT outperforms 97.10% of its industry peers.
  • In the last couple of years the Gross Margin of ACT has remained more or less at the same level.
Industry RankSector Rank
OM 15.93%
PM (TTM) 10.97%
GM 66.55%
OM growth 3Y17.53%
OM growth 5Y12.4%
PM growth 3Y14.29%
PM growth 5Y15.31%
GM growth 3Y2.01%
GM growth 5Y1.44%
ACT.DE Yearly Profit, Operating, Gross MarginsACT.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

9

2. Health

2.1 Basic Checks

  • ACT has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • Compared to 1 year ago, ACT has less shares outstanding
  • The number of shares outstanding for ACT has been reduced compared to 5 years ago.
  • The debt/assets ratio for ACT has been reduced compared to a year ago.
ACT.DE Yearly Shares OutstandingACT.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
ACT.DE Yearly Total Debt VS Total AssetsACT.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • An Altman-Z score of 5.15 indicates that ACT is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 5.15, ACT belongs to the best of the industry, outperforming 89.86% of the companies in the same industry.
  • The Debt to FCF ratio of ACT is 1.32, which is an excellent value as it means it would take ACT, only 1.32 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 1.32, ACT belongs to the best of the industry, outperforming 94.20% of the companies in the same industry.
  • A Debt/Equity ratio of 0.16 indicates that ACT is not too dependend on debt financing.
  • ACT has a Debt to Equity ratio of 0.16. This is in the better half of the industry: ACT outperforms 73.91% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF 1.32
Altman-Z 5.15
ROIC/WACC1.88
WACC7.15%
ACT.DE Yearly LT Debt VS Equity VS FCFACT.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

  • A Current Ratio of 2.87 indicates that ACT has no problem at all paying its short term obligations.
  • ACT has a better Current ratio (2.87) than 82.61% of its industry peers.
  • A Quick Ratio of 1.77 indicates that ACT should not have too much problems paying its short term obligations.
  • The Quick ratio of ACT (1.77) is better than 82.61% of its industry peers.
Industry RankSector Rank
Current Ratio 2.87
Quick Ratio 1.77
ACT.DE Yearly Current Assets VS Current LiabilitesACT.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

6

3. Growth

3.1 Past

  • ACT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 24.12%, which is quite impressive.
  • ACT shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 24.60% yearly.
  • ACT shows a small growth in Revenue. In the last year, the Revenue has grown by 1.05%.
  • The Revenue has been growing by 8.06% on average over the past years. This is quite good.
EPS 1Y (TTM)24.12%
EPS 3Y25.02%
EPS 5Y24.6%
EPS Q2Q%31.66%
Revenue 1Y (TTM)1.05%
Revenue growth 3Y9.49%
Revenue growth 5Y8.06%
Sales Q2Q%6.46%

3.2 Future

  • ACT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.26% yearly.
  • The Revenue is expected to grow by 6.02% on average over the next years.
EPS Next Y19.46%
EPS Next 2Y14.69%
EPS Next 3Y19.01%
EPS Next 5Y20.26%
Revenue Next Year2.51%
Revenue Next 2Y5.13%
Revenue Next 3Y8.61%
Revenue Next 5Y6.02%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ACT.DE Yearly Revenue VS EstimatesACT.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
ACT.DE Yearly EPS VS EstimatesACT.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2 4 6 8 10

4

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 26.56 indicates a quite expensive valuation of ACT.
  • The rest of the industry has a similar Price/Earnings ratio as ACT.
  • ACT's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.47.
  • The Price/Forward Earnings ratio is 24.18, which indicates a rather expensive current valuation of ACT.
  • ACT's Price/Forward Earnings ratio is in line with the industry average.
  • The average S&P500 Price/Forward Earnings ratio is at 24.26. ACT is around the same levels.
Industry RankSector Rank
PE 26.56
Fwd PE 24.18
ACT.DE Price Earnings VS Forward Price EarningsACT.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • ACT's Enterprise Value to EBITDA ratio is in line with the industry average.
  • ACT's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 47.13
EV/EBITDA 13.82
ACT.DE Per share dataACT.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The excellent profitability rating of ACT may justify a higher PE ratio.
  • ACT's earnings are expected to grow with 19.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.36
PEG (5Y)1.08
EPS Next 2Y14.69%
EPS Next 3Y19.01%

3

5. Dividend

5.1 Amount

  • ACT has a Yearly Dividend Yield of 1.10%.
  • ACT's Dividend Yield is slightly below the industry average, which is at 2.45.
  • Compared to an average S&P500 Dividend Yield of 1.89, ACT's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 1.1%

5.2 History

  • The dividend of ACT has a limited annual growth rate of 6.00%.
Dividend Growth(5Y)6%
Div Incr Years5
Div Non Decr Years5
ACT.DE Yearly Dividends per shareACT.DE Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2023 2024 2025 0.5 1 1.5

5.3 Sustainability

  • 49.16% of the earnings are spent on dividend by ACT. This is a bit on the high side, but may be sustainable.
  • ACT's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP49.16%
EPS Next 2Y14.69%
EPS Next 3Y19.01%
ACT.DE Yearly Income VS Free CF VS DividendACT.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M
ACT.DE Dividend Payout.ACT.DE Dividend Payout, showing the Payout Ratio.ACT.DE Dividend Payout.PayoutRetained Earnings

ALZCHEM GROUP AG

FRA:ACT (1/16/2026, 7:00:00 PM)

162

+1 (+0.62%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)10-30
Earnings (Next)02-27
Inst Owners40.91%
Inst Owner ChangeN/A
Ins Owners28%
Ins Owner ChangeN/A
Market Cap1.65B
Revenue(TTM)563.86M
Net Income(TTM)61.84M
Analysts86
Price Target175.9 (8.58%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.1%
Yearly Dividend1.2
Dividend Growth(5Y)6%
DP49.16%
Div Incr Years5
Div Non Decr Years5
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10.94%
PT rev (3m)8.9%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)1.01%
EPS NY rev (3m)1.72%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.31%
Revenue NY rev (3m)-0.37%
Valuation
Industry RankSector Rank
PE 26.56
Fwd PE 24.18
P/S 2.92
P/FCF 47.13
P/OCF 11.33
P/B 7.06
P/tB 7.17
EV/EBITDA 13.82
EPS(TTM)6.1
EY3.77%
EPS(NY)6.7
Fwd EY4.14%
FCF(TTM)3.44
FCFY2.12%
OCF(TTM)14.3
OCFY8.83%
SpS55.39
BVpS22.95
TBVpS22.6
PEG (NY)1.36
PEG (5Y)1.08
Graham Number56.13
Profitability
Industry RankSector Rank
ROA 10.49%
ROE 26.47%
ROCE 18.66%
ROIC 13.45%
ROICexc 16.12%
ROICexgc 16.26%
OM 15.93%
PM (TTM) 10.97%
GM 66.55%
FCFM 6.21%
ROA(3y)8.81%
ROA(5y)7.86%
ROE(3y)22.87%
ROE(5y)25.91%
ROIC(3y)12.06%
ROIC(5y)10.63%
ROICexc(3y)13.35%
ROICexc(5y)11.55%
ROICexgc(3y)13.5%
ROICexgc(5y)11.66%
ROCE(3y)16.73%
ROCE(5y)14.74%
ROICexgc growth 3Y25.57%
ROICexgc growth 5Y18.04%
ROICexc growth 3Y25.41%
ROICexc growth 5Y17.9%
OM growth 3Y17.53%
OM growth 5Y12.4%
PM growth 3Y14.29%
PM growth 5Y15.31%
GM growth 3Y2.01%
GM growth 5Y1.44%
F-Score6
Asset Turnover0.96
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF 1.32
Debt/EBITDA 0.33
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion 125.34%
Profit Quality 56.58%
Current Ratio 2.87
Quick Ratio 1.77
Altman-Z 5.15
F-Score6
WACC7.15%
ROIC/WACC1.88
Cap/Depr(3y)118.98%
Cap/Depr(5y)119.68%
Cap/Sales(3y)5.65%
Cap/Sales(5y)6.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.12%
EPS 3Y25.02%
EPS 5Y24.6%
EPS Q2Q%31.66%
EPS Next Y19.46%
EPS Next 2Y14.69%
EPS Next 3Y19.01%
EPS Next 5Y20.26%
Revenue 1Y (TTM)1.05%
Revenue growth 3Y9.49%
Revenue growth 5Y8.06%
Sales Q2Q%6.46%
Revenue Next Year2.51%
Revenue Next 2Y5.13%
Revenue Next 3Y8.61%
Revenue Next 5Y6.02%
EBIT growth 1Y16.7%
EBIT growth 3Y28.68%
EBIT growth 5Y21.47%
EBIT Next Year50.25%
EBIT Next 3Y28.31%
EBIT Next 5Y19.11%
FCF growth 1Y37.23%
FCF growth 3Y62.42%
FCF growth 5Y94.14%
OCF growth 1Y166.77%
OCF growth 3Y34.7%
OCF growth 5Y19.23%

ALZCHEM GROUP AG / ACT.DE FAQ

Can you provide the ChartMill fundamental rating for ALZCHEM GROUP AG?

ChartMill assigns a fundamental rating of 7 / 10 to ACT.DE.


What is the valuation status for ACT stock?

ChartMill assigns a valuation rating of 4 / 10 to ALZCHEM GROUP AG (ACT.DE). This can be considered as Fairly Valued.


Can you provide the profitability details for ALZCHEM GROUP AG?

ALZCHEM GROUP AG (ACT.DE) has a profitability rating of 9 / 10.


Can you provide the financial health for ACT stock?

The financial health rating of ALZCHEM GROUP AG (ACT.DE) is 9 / 10.


What is the earnings growth outlook for ALZCHEM GROUP AG?

The Earnings per Share (EPS) of ALZCHEM GROUP AG (ACT.DE) is expected to grow by 19.46% in the next year.